Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
5/28/2013
1
Health Issues in Breast Cancer Survivors
Michelle Melisko MD
Associate Clinical Professor of Medicine
UCSF Helen Diller Family Cancer Center
Cancer Survivors 2012 (U.S.)
5/28/2013
2
Trends in 5-Year Relative Survival Rates by Year of Diagnosis, All
Cancers, United States
5054
66
0
10
20
30
40
50
60
70
1975 to 1977 1984 to 1986 1996 to 2003
National Cancer Institute. SEER Cancer Statistics Review 2000-2004. http://seer.cancer.gov/csr/1975_2004/results_merged/topic_survival.pdf
Pat
ien
ts S
urv
ivin
g M
ore
Th
an 5
Yea
rs
Aft
er a
Can
cer
Dia
gn
osi
s (%
)
High Rates of Long-term Survival Among Breast Cancer Survivors
Horner MJ et al (eds). National Cancer Institute. http://seer.cancer.gov/csr/1975_2006. Accessed July 21, 2009.
9081
74
0
20
40
60
80
100
5 10 15
Pat
ien
ts A
live
(%
)
There are an estimated 2.5 million breast cancer survivors in the United States
Years After Diagnosis
5/28/2013
3
Survivorship Issues
• What is the impact on health of being a long-term cancer survivor?
• What is the cost of being a survivor—physically, emotionally, spiritually and financially?
• Is our healthcare system prepared to handle the growing number of people diagnosed with cancer, and the treatment and follow up needed for quality of life?
Differences in cancer follow up care - A world perspective
• In many countries, access to subspecialists is limited
• Primary care physicians and other “physician extenders” play a bigger role in health care in general
5/28/2013
4
GREAT BRITAIN• In a randomized trial of 296 women with a
history of breast cancer, transfer of routine oncology follow-up care to a family physician did not result in an increase in the time to diagnosis of recurrence
– Patient satisfaction was greater
– Health service costs were less
– Anxiety and health related quality of life were unaffected
Grunfeld E, Mant D, Yudkin P, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ 1996;313(7058):665-9.
CANADA
• 968 early-stage breast cancer patients who had completed adjuvant treatment were randomized to follow up in a cancer center or with their own family physician– No differences in number of recurrences, deaths,
recurrence related serious clinical events
– No difference in patient reported health-related quality of life
Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 2006;24(6):848-55.
5/28/2013
5
2005 Institutes of Medicine Guidelines on Survivorship
Key Recommendations: 1.All cancer stakeholders should work to raise
awareness of cancer survivorship and to establish this as a distinct phase of cancer treatment
2.Each patient should be given a Survivorship Care Plan reimbursed by insurers
3.Plan components should be developed and refined using evidence-based clinical practice guidelines and assessment tools
Hewitt M et al. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington DC: The National Academies Press; 2005.
ASCO Treatment Plan and Summary
Reproduced with permission from the American Society of Clinical Oncology.
http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Quality+Care/Quality+Measurement+%26
+Improvement/Chemotherapy+Treatment+Plan+and+Summary. Accessed June 10, 2009.
Name, age, contact information
Breast cancer diagnosis
Surgery (type/dates)
Patient history, including comorbid conditions
Overview of page 2 (not shown)
– Hormonal therapy (agent, duration, date to be initiated)
– Trastuzumab (dates, ejection fraction)
– Provider contacts (including referrals)
– Pre- and posttreatment comments (eg, baseline assessments, patient counseling, follow-up recommendations)
Adjuvant chemotherapy/radiation therapy (planned and received)
– Details on agents/doses prescribed (dates initiated/completed)
– Toxicities (anticipated, experienced)
5/28/2013
6
ASCO Survivorship Care PlanFollow-Up Care Providers to Contact
Medical history and physical examination
• First 5 years
• Year 6+
Posttreatmentmammography
• First 5 years
• Year 6+
Breast self-examination • N/A
Pelvic examination Ob/gyn
Coordination of care • First 5 years
• Year 6+
Genetic counseling If indicated, based on risk factors
Follow-Up Care Visit Frequency
Medical history and physical examination
• Years 1 to 3: every 3 or 6 months (including key notes for 1st-year visits)
• Years 4 to 5: every 6 or 12 months
Mammography • Every 6 or 12 months as indicated
Notes • May include any relevant patient notes and/or recommendations
Breast Cancer Survivorship Care Plan. v1.0 09/07.
http://www.asco.org/ASCO/Downloads/Cancer/Survivorship%20Plan%209.07.doc. Accessed May 27, 2009.
Hewitt M, et al. eds. From Cancer Patient to Cancer Survivor: Lost in Transition.Washington DC; The National Academies Press; 2005.
Essential Components of Survivorship Care
Treating the consequences of cancer and its
treatments
Recurrence, new cancers, late effects
Recurrence, second cancers, and assessing medical and psychosocial late effects
Interdisciplinary coordination between PCPs and specialists
5/28/2013
7
Optimizing Survivorship Care: Practice Considerations and Barriers in the Community
1.Fragmented system of care
2.Lack of training
3.Absence of agreed-upon standards of care
4.Reimbursement
5.Communication
Hewitt M, et al. From Cancer Patient to Cancer Survivor: Lost in Transition.Washington DC: The National Academies Press; 2005.
• 56 year old postmenopausal woman is diagnosed with a Stage I invasive ductal carcinoma
– 1.5 cm grade 2 IDC
– ER positive, PR positive, HER2 negative
– She is treated with a lumpectomy, SLND, and radiation to the breast
– She has recently started on an aromatase inhibitor
She comes to see her primary care MD for routine health care and is extremely worried about breast cancer recurrence. She wants to have lab tests and scans to “make sure her cancer hasn’t come back”.
5/28/2013
8
What are the chances that this patient will die of breast cancer
in the next 10 years?
1. < 5%2. 5-10% 3. 10-20%
Should you order any lab tests or scans to follow up on her cancer?
Breast Cancer Follow Up:What to do and What NOT to do
• American Society of Clinical Oncology 2013 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting (JCO March 1 2013)– Routine labs, CT scans, bone scans are not
necessary or indicated
• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast (JCO Nov 20 2007: 5287-5312)– TUMOR MARKERS ARE NOT RECOMMENDED
5/28/2013
9
Breast Imaging Recommendations• NCCN, ACSO, and ACS guidelines recommend follow up
mammograms every 6-12 months for affected breast in the setting of breast conserving surgery
• Breast MRI only indicated for the following:– Pts with equivocal mammographic and/or US at primary diagnosis– Pts presenting with malignant axillary adenopathy and unknown site of
primary tumor– Patient with extensive or locally advanced cancer undergoing
chemotherapy– Screening of women at increased ( 20% to 25%) lifetime risk
• Known BRCA1 or BRCA2 gene mutation carrier• Pt with first-degree relative with a BRCA1 or BRCA2 gene mutation who
has not had genetic testing themselves • Radiation therapy to the chest between the ages of 10-30 yo• Genetic disease such as Li-Fraumeni or Cowden syndrome or one of
these syndromes in first-degree relatives
Orel S, JCO Feb 2008
Critical Issues in Cancer Survivorship
• Cancer survivors are at risk for a range of late physical effects and emotional and practical issues due to their primary treatment
ASCO. Cancer Advances Information from the Experts: Cancer Survivorship—Increasing Survival, Improving Lives. December 2004.
Physical Effects Emotional Issues Practical Issues
Fatigue Chronic pain or neuropathy Organ damage Cognitive dysfunction Sexual dysfunction Premature menopause or
infertility Osteoporosis Lymphedema
Increased concerns about the future and health
Sadness, depression, and sense of loss
Coping with stopping treatment Relationship issues
Financial issues and insurance coverage
Employment/workplace discrimination
Obtaining future medical or life insurance
5/28/2013
10
Spectrum of Potential Side Effects
Hayes DF. N Engl J Med. 2007;356:2505-2513.
Hot flashes/night sweats
Arthralgia/joint symptoms
Sexual dysfunction
Cognitivedysfunction
Depression
Genitourinary symptoms
Other 2nd-malignancy(ie, endometrial cancer)
Chronic fatigue
Cardiovascular effects
Osteoporosis/bone fractures
Early breast cancertreatments including:
Radiation therapyChemotherapy
Monoclonal antibodyHormonal therapy
Weight gain
Symptom/Side-Effect Management
Cardiovascular and Thrombotic Effects in Breast Cancer Survivors
Hormonal Therapy
Potential Cardiovascular or ThromboticAdverse Effects
Anthracycline-Based Chemotherapy
TrastuzumabRadiation Therapy
1. Carver JR, et al. J Clin Oncol. 2007;25:1-18. 2. Mrozek MD, Shapiro CL. Clin Adv Hematol Oncol. 2005;3:211-222. 3. Hayes DF. N Engl J Med. 2007;356:2505-2513.
• Many early breast cancer survivors receive a combination of treatments associated with cardiovascular and/or thromboticside effects1-3
5/28/2013
11
Thrombotic Effects of Cancer Treatment
• Tamoxifen increases the risk of thromboembolic events and cerebrovascular disease by approximately threefold1,2
• A meta-analysis indicated a 29% increase in risk of stroke in women randomized to tamoxifen vs placebo or other therapies3
• Concurrent combination of chemotherapy and tamoxifenhas been associated with a further increased risk of thromboembolism4
1. Hayes DF. N Engl J Med. 2007;356:2505-2513. 2. Mrozek MD, Shapiro CL. Clin Adv Hematol Oncol. 2005;3:211-222. 3. Bushnell CD, Goldstein LB. Neurology. 2004;63:1230-1233. 4. Pritchard KI, et al. J Clin Oncol. 1996;14:2731-2737.
Cardiotoxicity Overview
• Extensive data regarding anthracycline mechanism for cardiac injury, but little data regarding treatment
• Over 50% of children with cancer will be exposed to anthracycline based therapy
• Tyrosine Kinase inhibitors (Sunitinib, Imatinib, Dasatinib, etc) have been in use <10 yrs
– Extensive number of TKI trials ongoing
– >50% of these trials have pathways that are shared in cardiac signaling
5/28/2013
12
Frequency of Deaths by Different Causes in the Childhood Cancer Survivor Study
Total DeathsNo. 2,534 %
Recurrence/progressive disease 1,469 58.0
Medical Causes of Death 879 34.7
- Subsequent neoplasm 470 18.5
- Diseases of the circulatory system 176 6.9
- Diseases of the respiratory system 67 2.6
Armstrong GT et al. JCO.2009;27:2328-2338
Late Mortality Among 5 Year Survivors of Childhood Cancer (CCSS)
Tukenova M et al. JCO.2010;28:1308-1315
Role of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer
5/28/2013
13
Doxorubicin: Dose-Relationships
• Retrospective review of 4018 patients who received doxorubicin
• Definition of doxorubicin-induced CHF: Clinical signs/symptoms of CHF believed to be secondary to doxorubicin by the clinician
• Findings:
– Overall incidence: 2.2% (n=88).
– ‘Inflection point’ at 550 mg/m2
(7%)
Adapted from Von Hoff et al. Ann Int Med. 1979;91:710-7.
A More Recent Look at the Data…
• Analysis of the placebo-arms of three dexrazoxane trials
• In all trials: Normal LVEF at start• MUGA performed at baseline & after
every 50 mg/m2 of doxorubicin
• Examined rate of significant EF drop or symptomatic HF
• Almost identical data later shown in post-anthracycline echos in breast cancer patients in B-31 & N-9831 trials
Adapted from Swain et al. Cancer. 2003;97:2869-79.
5/28/2013
14
• 703 patients (216 males)
• Age 47±12 years
• Treated with HDC for poor prognosis malignancies
• Follow-up = 48 months
• MACE (Major Adverse Cardiac Event) incidence
Tn I serum determination: Baseline = before HDC Early = soon after HDC (0,12,24,36,72 hours) Late = 1 month after HDC
Circulation 2004
Results
TnI +/-n = 145 pts (21%)
TnI +/+n = 63 pts (9%)
TnI -/-n = 495 pts (70%)
5/28/2013
15
Left ventricular ejection fraction
TnI +/+
TnI -/-
(%)
40
45
50
55
60
65
0 1 3 6 12 18 48 months
TnI +/-
Cardinale et al. Circulation 2004
§
*§
* = p<0.01 vs. TnI -/-; = p<0.01 vs. TnI +/-.
* **
*
** *
*§ §
Cardiac Events3.5 year-follow-up
Sudden death
Cardiac death
Acute pulmonary edema
Heart failureAsymptomatic LVEF >25%
Life-threatening arrhythmias
Conduction disturbancesrequiring PM implantation
PersistentTnI +
NegativeTnI
TransientTnI +
Circulation 2004
1%
*= p<0.001 vs. TnI -
37%*
#= p<0.001 vs. TnI +-
84%* #
5/28/2013
16
Circulation 2006
Pat
ient
s(%
)
ACEI group
0
20
40
0%
43%
p<0.001
Controls
50
30
10
(n=0) (n=25)
Primary end-point:LVEF decrease >10 percent units + <50%
Troponin I Early Positivity
Enalapril
n = 56 pts
Controls
n = 58 pts
physical examination, ECG, ECHO: b,1,3,6,12 months
started 1 month after HDC continued for 1 year
443 ptsHigh-dose CT
TnI + = 114 pts (24%)
5/28/2013
17
Secondary end-pointsfollow-up 12 months
Sudden death 0 (0%) 0 (0%) 0 (0%) NSCardiac death 2 (2%) 0 (0%) 2 (3%) NSAcute pulmonary edema 4 (2%) 0 (0%) 4 (3%) NSHeart failure 14 (12%) 0 (0%) 14 (22%) <0.001Life-threatening arrhythmias 11 (10%) 1 (2%) 10 (16%) 0.01
CUMULATIVE EVENTS 31 (28%) 1 (2%) 30 (52%) 0.001
Totaln=112 PACEI
n=54Controls
n=58
Cardinale et al. Circulation 2006
Cancer 2005; 104:2492-8
Valsartan for Prevention of Cardiotoxicity•40 patients with NHL randomized to receive CHOP with or without 80 mg/day of valsartan
•Acute cardiotoxicity evaluated before and on days 3, 5, and 7 after CHOP
•CHOP induced transient increases in the LVEDD on ECHO, the QTc interval and QTc dispersion on EKG, and in the plasma BNP. All these changes returned to nearly normal levels within a week after CHOP (P < 0.001)
•Valsartan significantly prevented all these changes except for the elevation in BNP(P < 0.05).
5/28/2013
18
Protective Effects of Carvedilol Against
Anthracycline-Induced Cardiomyopathy
Kalay et al. JACC. Dec 2006. 48:2258-62Data expressed as mean values.
•25 pts in whom ANT therapy was planned were randomized to carvedilol or control. Carvedilol was given 12.5 mg qd for 6 months during chemo
•Pts were evaluated with ECHO before and after chemotherapy.
•At the end of 6 months of follow-up, 1 patient in the carvedilol group and 4 in the control group had died
•Control EF was below 50% in 1 patient in the carvedilol group and in 5 in the control group.
•Mean EF of the carvedilol group was similar at baseline and fupl echocardiography (70.5 vs. 69.7, respectively; p = 0.3), but in the control group the mean EF at fup ECHO was significantly lower (68.9 vs. 52.3; p < 0.001)
Efficiency of Atorvastatin in the Protection of Anthracycline Induced Cardiomyopathy
JACC Vol 58:2011 Randomized to Lipitor 40mg or Placebo
5/28/2013
19
High Mortality Rates Associated with Withdrawal of Beta Blockers and Ace Inhibitors in Chemotherapy-
Induced Heart Failure
Circulation. 2008;118:S_797
DRUG HYPERTENSION (%)
Bevacizumab (Avastin) Hypertension (23% to 34%)
Sunitinib (Sutent) Hypertension (>15%)
Alemtuzumab (Campath) Hypertension ( 11%)
Gemtuzumab (Mylotarg) Hypertension ( >5%)
Infliximab (Remicade) Hypertension (10%)
Muromanoab-CD3 (Orthoclone® OKT 3)
Hypertension ( < 1%)
Rituximab (Rituxan) Hypertension (6%)
Drug-Induced Hypertension with FDA
Approved Cancer Therapies
5/28/2013
20
Drug-Induced HF of FDA Approved Targeted Cancer Therapies
Sorafenib (Nexavar) 2007 VEGF1,2,3/PDGF 1%
Dasatinib (BMS-354825) 2006 BCR-ABL/SRC C-Kit,PDGF
4%
Sunitinib (Sutent) 2006 VEGF/PDGF/
C-KIT
3-14%
Bevacizumab (Avastin) 2004 VEGF 2-14%
Trastuzumab (Herceptin) 2000 ErbB-2/TKI 3-27%
Imatinib (Gleevec) 2001 C-ABL, C-Kit 1%
Drug Approval Action CHF
Chemotherapy-induced Neuropathy: Natural History, Prevention, and Treatment
5/28/2013
21
Persistent Peripheral Neuropathy in Breast Cancer Survivors Treated With Taxane Chemotherapy
• Study design:
– 35 pts receiving adjuvant paclitaxel for breast cancer followed for a median of 14 months following taxane therapy.
– Quantitative sensory testing, FACT-Tax and Neuropathic Pain Scale assessments, and serum levels of nerve growth factor were evaluated.
• Results:
– Overall, significant peripheral neuropathy (> 60%) was seen a year or more after taxane therapy completion
Patients With Neuropathy (%)
Patients With Moderate-to-Severe
Neuropathy (%)
Numbness in Hands 66% 34%
Numbness in Feet 64% 36%
Pain in Hands 68% 41%
Pain in Feet 65% 44%
Crew, SABCS 2007, Abstract 6089
Many cancer drugs cause neuropathy
• Paclitaxel
• Docetaxel
• Abraxane
• Ixabepilone
• Vinorelbine
• Oxaliplatin
• Eribulin
• Velcade (proteosome inhibitor)
5/28/2013
22
Patients scheduled to receive IV paclitaxel at one of 2 dose/schedules175+ mg/m2 Q 3 wks70-90 mg/m2 weekly
Patient questionnaires looking at the incidence and severity of paclitaxel-associated acute pain and sensory neuropathy.
Paclitaxel-Associated Acute Pain Syndrome: Natural History Study N08C1
Daily Mean Pain Scores (Q 3 Week)
Mea
n P
-AP
S P
ain
2 3 4 5 6 7 *2 3 4 5 6 7 2 3 4 5 6 7
*Cycle 4, day 2
Cycle 1 Cycle 2 Cycle 3
Day Day Day
0
1-4
5-6
7-10
5
0
2
3
4
1
6
7
8
9
10
5/28/2013
23
0
60
80
100
1 2 3 4 5 6 7 8 9 10 11 12
EORTC CIPN-20 Data (Weekly)
Cycles
Bas
elin
e va
lues
(%
)
40
0
n= 100 99 95 98 98 96 95 95 93 93 93 91 94n= 100 99 98 98 96 95 94 93 91 90 90 89 88n= 100 98 96 94 92 90 87 85 83 80 80 77 76
Sensory
AutonomicMotor90
70
50
P< 0.0001
100
0
40
50
60
70
0 2 3 4 5 6 7 8 9 10 11 12
80
90
1
EORTC CIPN-20 Tingling, Numbness and Pain Scores – Hands (Weekly)
n= 91 85 83 80 87 87 84 84 77 79 70 66 58n= 91 85 83 80 87 87 83 84 77 79 70 66 57n= 91 85 83 80 87 87 84 84 77 79 70 66 58
Cycles
Numbness
Pain
Tingling
CIP
N-2
0 S
core
s
5/28/2013
24
Selected CIPN Clinical Trials
• Gabapentin
• Scrambler therapy
• Photon Simulator (Near Infared Light)
CP1347589-47
Gabapentin Study Schema
R
6 wk6 wkGabapentinGabapentin2700 mg/day2700 mg/day
PlaceboPlacebo
6 wk6 wk PlaceboPlaceboGabapentinGabapentin2700 mg/day2700 mg/day
2 wk2 wk WashoutWashout
Chemotherapy-induced neuropathyChemotherapy-induced neuropathy
CP1347589-48Cancer 110(9):2110, 2007Cancer 110(9):2110, 2007
5/28/2013
25
0
2
4
6
8
10
0 2 4 6 8 10 12 14
Placebo
Gabapentin
Meanpain
intensity
Meanpain
intensity
WeekWeek
P=0.21P=0.21 P=0.37P=0.37
First periodFirst periodWash-
outWash-
out Second periodSecond period
Mean Pain Intensity
CP1347589-49
Placebo
Gabapentin
Cancer 110(9):2110, 2007Cancer 110(9):2110, 2007
Pilot trial of a Patient-specific Cutaneous Electro-stimulation Device (MC5-A Calmare®)
for Chemotherapy Induced Peripheral Neuropathy
Thomas J. Smith MD, Patrick J. Coyne RN MSN, Patricia Dodson BSN MA, , Gwendolyn Parker RN MSN, V. Ramakrishnan, PhD
Massey Cancer Center of Virginia Commonwealth University
5/28/2013
26
MC5-A Calmare™• Patient-specific cutaneous electro-stimulation similar to
spinal cord stimulation, but non-invasive
• Creates "non pain" information in packets of rapidly varying impulses, given non-invasively using the patients own nerves
• 30 minute long sessions using EKG pads. Above and below pain, on dermatomes.
• Stinging, then tingling; adjust to tolerance.
• US FDA approved Feb 09.
0
1
2
3
4
5
6
7
1 2 3 4 5 6 7 8 9 10
Days of therapy
CIP
N P
ain
Sco
re 0
-10
CIPN Mean
Unadjusted CIPN "pain now" scores
Results
5/28/2013
27
Characterization and Treatment of Chemotherapy Neuropathy (CIN)
Recruiting patients with (n=400) and without (n=200) chemo-induced neuropathy (CIN) whom received taxanes, platinum-based, or both classes of CTX agents and completed therapy
Pts will come to the CRS at Mt Zion once for an interview, neurological testing, and a blood collection for a candidate gene analysis
Characterization and Treatment of Chemotherapy Neuropathy:
Intervention Arm Pts with CIN in their feet may enroll in a RCT of the
photon stimulator, a device that delivers near-infrared light
The LED diode wavelength for this study is 870 nanometers– When activated, the photon stimulator is preset to deliver
1800 Joules in a 7 minute treatment period.
– Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period
5/28/2013
28
What medications breast cancer patients might be taking
And what to worry about with these medications…
Tamoxifen
• Tamoxifen has been shown to decrease disease recurrence and increase overall survival
• Remains the standard of care for pre-menopausal breast cancer patients
• CYP2D6 pharmacogenetics varies and results in different levels of therapeutic efficacy– Certain antidepressants should be avoided in patients
on tamoxifen
• Tamoxifen use has been associated with endometrial cancer and thromboembolism
EBCTG. Lancet. 1998;351:1451-1467 (A); Johnston et al. Nat Rev Cancer. 2003;3:821-831(B); Knox et al. Presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2006; Atlanta, Ga (A).
5/28/2013
29
Acute effects of tamoxifen and AIs on menopausal symptoms in breast cancer
patients• Prospective study of 181 consecutive
postmenopausal women starting hormonal therapy
• Both first line tamoxifen and AIs increased occurrence and severity of hot flashes
• Musculoskeletal pain and dyspareunia significantly increased with AIs
• Sexual interest decreased significantly with tamoxifen
• Younger age was associated with more hot flashes and vaginal dryness
Morales et al, Anti-Cancer Drugs 2004
Changes in menopausal symptomsSymptom AI
(Baseline)
AI
(3 mo)
TAM
(Baseline)
TAM
(3 mo)
Hot flashes 54/46/0 23/69/8 52/44/4 13/64/23
Musculoskeletal
Pain
36/57/7 18/46/36 56/40/4 40/53/6
Vaginal Dryness 67/32/0 50/46/4 65/27/8 53/32/15
Dyspareunia 68/21/11 37/37/25 74/18/8 50/38/12
Decreased sexual interest
63/21/16 31/37/31 53/37/10 21/32/47
Emotional disturbance
45/50/5 53/47/0 35/56/8 27/64/9
(no symptom or mild/mod-severe/intolerable)
5/28/2013
30
Aromatase Inhibitors
• AIs have been shown to decrease disease recurrence compared with tamoxifen
• Several regimens have been shown to be more effective than 5 yrs of tamoxifen alone – 5 yrs of adjuvant AI therapy
– 2 to 3 yrs of tamoxifen, followed by 2 to 3 yrs of an AI
– 5 yrs of tamoxifen, followed by 5 yrs of AI
Winer et al. J Clin Oncol. 2005;23:619-629 (A).
Your breast cancer patient comes in to see you three months later and is complaining of pain in her right hip and also stiffness in her
hands. She says she has tried acetominophen without relief. What should
you do?
1. Reassure patient that joint pains are a common side effect of the aromatase inhibitors.
2. Order plain films of her hands and/or hip
3. Order a bone scan
4. Suggest she try NSAIDS and exercise
5/28/2013
31
Musculoskeletal Events: Bone Health
• During treatment, aromatase inhibitors (AIs):
– Reduce estrogen
– Are associated with a decline in BMD and an increased risk of fracture
– Exacerbate the normal progressive loss of BMD in postmenopausal women
• In contrast, tamoxifen may preserve BMD• Osteoporosis/increased fracture risk are serious health issues for
breast cancer survivors• Patients with osteopenia/osteoporosis prior to initiation of AI
therapy may be at the greatest risk
BMD=bone mineral density.Chien AJ, Goss PE. J Clin Oncol. 2006;24:5305-5312; Gralow JR. J Clin Oncol. 25:1-4; Hilner BE et al. J Clin Oncol. 2003;21:4042-4057; Grey AB, et al. Am J Med. 1995;99:636-641; Marttunen MB, et al. J Clin Endocrinol Metab. 1998;83:1158-1162; Eastell R, et al. J Clin Oncol. 2008;26:1051-1058.
Monitoring of bone density while on an aromatase inhibitor
• Most patients should have a bone density tested within one year of starting an AI
• Recommend patients with normal BMD at baseline to take calcium, vit D, and pursue weight bearing exercise
• Patients with osteopenia should have BMD rechecked one year later to assess change
• Patients with osteoporosis at baseline or during follow up should consider bisphosphonate therapy
• Osteoporosis is not a contraindication to taking an aromatase inhibitor
5/28/2013
32
Aromatase Inhibitors and Bone LossIV bisphosphonates may decrease AI-associated bone loss
Z-FAST study evaluated 36-month safety and efficacy of upfront vs delayed IV ZA in decreasing AI-associated bone loss in postmenopausal
women with early breast cancer
Brufsky et al. J Clin Oncol 25:829-836
Musculoskeletal Events: Joint Symptoms
• AIs are associated with significantly higher rates of joint symptoms/arthralgias vs tamoxifen1
– Typical onset within 2 months of treatment initiation1
– Symptoms may resolve over time2
– The true etiology and the optimal treatment is not known1
1. Burstein HJ. Breast. 2007;16:223-234. 2. Buzdar AU, for the ATAC Trialists’ Group. Presented at: 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, GA. Abstract 551.
5/28/2013
33
ATAC Substudy: Risk Factors for Developing Joint Symptoms
Sestak I, et al. SABCS 2007. Abstract 2071.
Risk FactorJoint Symptoms, n
(%)Multivariate OR (95%
CI)P Value
Anastrozole 1040 (37.2) 1.31 (1.16-1.47) < .001
Previous HRT 840 (42.3) 1.52 (1.35-1.72) < .001
Chemotherapy 485 (38.9) 1.20 (1.04-1.38) .01
HR negative 130 (27.7) 0.76 (0.61-0.85) .02
Region of origin (vs rest of world)
• UK 563 (30.2) 1.19 (1.01-1.37) .04
• North America 803 (47.7) 2.1 (1.81-2.43) < .001
BMI > 30 kg/m2 (vs < 25)
555 (39.3) 1.36 (1.17-1.57) < .001
• Use of previous HRT led to greater difference in joint symptoms between patients on anastrozole vs tamoxifen
Estrogen Deprivation:Vasomotor Symptoms
• Chemotherapy can induce ovarian failure
• Hormone therapy can exacerbate vasomotor symptoms
• Hot flashes and sleep disturbances are common
• May lead to additional physical and psychosocial symptoms including mood lability
1. Hayes DF. N Engl J Med. 2007;356:2505-2513; 2. Barton DL, et al. Supportive Cancer Therapy. 2006;3:91-7. 3. Mrozek MD, Shapiro CL. Clin Adv Hematol Oncol. 2005;3:211-222.
5/28/2013
34
Management of hot flashes in breast cancer
• Placebo effect– Several placebo controlled studies have
shown that placebo can decrease hot flashes by 25% over 3-4 week period
– 10% of women may >75% reduction
– 10% will have a 50-75% reduction
Loprinzi et al, Lancet Oncol 2001
Phyto-estrogens
• NCCTG found no evidence of efficacy or toxicity from soy phyto-estrogen equivalent of 3 glasses of soy milk
• Small placebo controlled randomized trial found 50 mg of soy isoflavone equivalent to reduce hot flashes by 45% (c/w 25% in control arm)
• Larger randomized trial of soy preparation found statistically significant decrease in hot flashes at 6 weeks (p=0.03) but not at 12 wks
Quella et al, JCO 2000; Scambia et al, Menopause 2000; Upmalis et al, Menopause 2000
5/28/2013
35
Progestational Agents
• Megestrol acetate (Megace) tested in placebo controlled, double-blinded, randomized crossover trial in men and women– Megace reduced hot flashes by 75-80% c/w 20% with
placebo– Women on tamoxifen had transient increase in hot
flashes, resolving in 2-3 wks– Well tolerated but many pts d/c’d treatment due to
perceived side effects (weight gain)
• Attractive option in metastatic breast cancer pts due to anti-cancer effects of Megace
Loprinzi et al, NEJM 1994; Quella et al, Cancer 1998; Burch et al, JCO 1999
Other “Safe”Options• Vitamin E
– Double blind placebo controlled trial in breast cancer survivors
– 800 IU/day was slightly more effective than placebo, decreased hot flash frequency by one per day
• Black Cohash– Herb, Cimicifuga racemosa, approved in Germany for
menopausal symptoms– Ongoing trials in US and Europe with mixed results
• Bellergal– Several small studies showed decrease in hot flash
frequency (at 2 wks only) and severity (retrospective)
5/28/2013
36
Mean Hot Flash Score Reduction Randomized Studies
0
20
40
60
80
100
0 1 2 3 4 5 6
Week
% R
edu
ctio
n (
Mea
n) Placebo (n=420)
Soy (n=78)
Clonidine (n=75)
Megestrol (n=74)
Fluoxetine (n=36)
Venlafaxine (n=48)
Vitamin E (n=53)
Black Cohosh (n=58)
Ven (vs MPA) (n=94)
MPA 400 mg (n=94)
0
20
40
60
80
100
Baseline 1 2 3 4 5 6Weeks
Ho
t fl
ash
sco
re
(per
cen
t o
f b
asel
ine)
Placebo
Venlafaxine 37.5 mg/d
Venlafaxine 150 mg/dVenlafaxine 75 mg/d
Loprinzi et al, Lancet 2000
Venlafaxine for Hot Flashes
5/28/2013
37
Gabapentin for Hot Flashes
Placebo
Gabapentin 300 mg
0
-10
-6
Week 4
Change from baseline in hot flash severity
Baseline
-8
-4
-2
Week 8
Gabapentin 900 mg
-12
-14
Pandya KJ et al. Lancet 2005;366:818–824.
• 40% to 100% of cancer survivors report some form of sexual dysfunction (ie, vaginal dryness, painful intercourse)1
• Multiple dimensions2:
– Psychological/body image
– Hormonal treatment effects
• After primary treatment with mastectomy and chemotherapy3:
– 34% of women lacked sexual interest
– ~25% of women report difficulty with arousal, orgasm, or lubrication
Estrogen Deprivation: Sexual Dysfunction Symptoms
1. Krychman ML, et al. Oncology. 2006;71:18-25. 2. Hayes DF. N Engl J Med. 2007;356:2505-2513. 3. Ganz PA, et al. J Natl Cancer Inst. 2004;96:376-387. 4. Ganz PA. J Clin Oncol. 2006;24:5105-5111.
5/28/2013
38
Vaginal Dryness
• Non-estrogenic vaginal lubricants (Replens)
• Vaginal estrogens (ESTRING or Vagifem )
• Vaginal Testosterone Cream or DHEA
Loprinzi et al JCO 15, 969-973; 1997
Replens
PlaceboReplens
Placebo
Replens for vaginal dryness
5/28/2013
39
Are vaginal estrogens safe in breast cancer patients?
The jury is still out…
Vagifem - Controversial• Prospectively measured the serum E
levels in 6 women on adjuvant AI therapy for early breast cancer using Vagifem
• All were prescribed Vagifem 25 mcg tablets administered qd for 2 wks then twice wkly
• Serum was analyzed for E, FSH and LH at baseline then 2, 4, 7–10 and 12 weeks since commencement of vaginal estradiol
• Serum E levels rose from baseline levels ≤5 pmol/l consistent with AI therapy to a mean 72 pmol/l at 2 weeks. By 4 weeks this had decreased to <35 pmol/l in the majority (median 16 pmol/l) although significant further rises were seen in two women
Kendall et al, Annals of Oncology 17: 584–587, 2006
5/28/2013
40
Transdermal Testosterone in Female Cancer Survivors with Decreased Libido –
NCCTG N02C3
R
4 weeks
Testosterone*10 mg/day
Placebo**
4 weeks
Placebo**
Testosterone*10 mg/day
*In Vanicream** Vanicream JCO 24:469S, 2006 ASCO abstract #8507
-1
0
1
2
1stperiod
2ndPeriod
placebotestosterone
Mean Change from baseline:
Free testosterone concentrations
ng/dl
P<.0001
(Norms: 0.3-1.9 ng/dl)
Testosterone
5/28/2013
41
Libido Change from Baseline
0
1
2
3
4
5
6
7
8
9
1st Period 2nd Period
placebotestosterone
P=0.58 P=0.71
What other long term health and QOL issues may be in store for
your breast cancer patient?
• Weight gain
• Unfavorable lipid profiles?
• Persistent cognitive complaints?
• Chronic fatigue?
5/28/2013
42
What Are the Most Essential Aspects Required to Optimize Survivorship Care?
a)Monitoring for recurrenceb)Managing treatment-related side effectsc)Adherence to therapyd)Overall wellness promotione)Emotional healthf) Coordination of careg)Monitoring late effects of treatmenth)Patient/caregiver counseling/education about
recurrence riski) Referralsj) Other
Breast Cancer Survivorship Alliance. Health Care Professional Survey: Assessment of Survivorship Awareness and Educational Needs. Conducted at: 30th Annual San Antonio Breast Cancer Symposium; December 13-17, 2007; San Antonio, TX.
Potential Impact of Lifestyle Factors on Survivorship
Diet and Weight
• Weight and weight gain may be associated with higher rates of breast cancer recurrence and mortality
• One study suggests that a low fat diet high may be associated with a decreased risk of recurrence2
Exercise
• Regular moderate exercise may improve survival, particularly in women with hormone receptor–positive tumors3
Alcohol• Limited alcohol consumption is recommended by the
NCCN to promote a healthy lifestyle4
1. Kroenke CH et al. J Clin Oncol. 2005;23:1370-1378 2. Chlebowski RT et al. J Natl Cancer Inst. 2006;98:1767-1775 3. Holmes MD et al. JAMA. 2009;293:2479-2486. 4. National Comprehensive Cancer Network. Breast Cancer Risk Reduction-v.2.2009. http://www.nccn.org/professionals/physician_gls/PDF/breast_risk.pdf. Accessed September 15, 2009.
5/28/2013
43
Takeaway Messages for HCPs of Breast Cancer Survivors
• Cancer patients face many long term complications and symptoms from their treatment
• Many cancer patients will be cured of their disease– Not every symptom is a recurrence of cancer!!
– Before you order a scan or test, consider contacting patient’s treating oncologist to discuss what test would be best and what the implications will be